𝙄𝙉𝘼𝘼𝙌𝘾 ᴮᴼ

Startpagina
België
Brussels
𝙄𝙉𝘼𝘼𝙌𝘾 ᴮᴼ

An 𝓲𝓷𝓲𝓽𝓲𝓪𝓽𝓲𝓿𝓮 that encourages 𝕋𝔼𝔸𝕄𝕎𝕆ℝ𝕂 towards «science, education and technology».

13/10/2025

E-learning | 𝙄𝙉𝘼𝘼𝙌𝘾 ᴮᴼ
---------------------------------
𝙵𝙾𝚁 𝙷𝙴𝙰𝙻𝚃𝙷𝙲𝙰𝚁𝙴 𝙿𝚁𝙾𝚅𝙸𝙳𝙴𝚁𝚂 / 𝙿𝙰𝚁𝙰 𝙿𝚁𝙾𝚅𝙴𝙴𝙳𝙾𝚁𝙴𝚂 𝙳𝙴 𝚂𝙰𝙻𝚄𝙳
𝐏𝐚𝐭𝐢𝐞𝐧𝐭-𝐂𝐞𝐧𝐭𝐞𝐫𝐞𝐝 𝐀𝐩𝐩𝐫𝐨𝐚𝐜𝐡𝐞𝐬 𝐭𝐨 𝐍𝐚𝐯𝐢𝐠𝐚𝐭𝐢𝐧𝐠 𝐌𝐮𝐥𝐭𝐢𝐩𝐥𝐞 𝐒𝐜𝐥𝐞𝐫𝐨𝐬𝐢𝐬 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐏𝐫𝐨𝐠𝐫𝐞𝐬𝐬𝐢𝐨𝐧: 𝐀 𝐓𝐨𝐨𝐥𝐤𝐢𝐭 𝐟𝐨𝐫 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐏𝐫𝐨𝐯𝐢𝐝𝐞𝐫𝐬 𝐚𝐧𝐝 𝐓𝐡𝐞𝐢𝐫 𝐏𝐚𝐭𝐢𝐞𝐧𝐭𝐬
This toolkit includes practical approaches to guide providers and patients in detecting subtle signs of MS progression and offers comprehensive strategies for developing treatment plans based on current evidence and patient-centered practices.

🚥 𝗦𝘁𝗮𝗿𝘁 𝗮𝗰𝘁𝗶𝘃𝗶𝘁𝘆: https://primeinc.org/online/patient-centered-approaches-navigating-multiple-sclerosis-disease-progression
---------------------------------
✔ 𝗘 -𝗹𝗲𝗮𝗿𝗻𝗶𝗻𝗴: https://www.inaaqc.org/e-learning

12/10/2025

𝐃𝐚𝐩𝐚𝐠𝐥𝐢𝐟𝐥𝐨𝐳𝐢𝐧𝐚 𝐦á𝐬 𝐫𝐞𝐬𝐭𝐫𝐢𝐜𝐜𝐢ó𝐧 𝐜𝐚𝐥ó𝐫𝐢𝐜𝐚 𝐩𝐚𝐫𝐚 𝐥𝐚 𝐫𝐞𝐦𝐢𝐬𝐢ó𝐧 𝐝𝐞 𝐥𝐚 𝐝𝐢𝐚𝐛𝐞𝐭𝐞𝐬 𝐭𝐢𝐩𝐨 𝟐
En conclusión, el régimen de dapagliflozina más restricción calórica regular logró una tasa mucho mayor de remisión de la diabetes en comparación con la restricción calórica sola en pacientes con sobrepeso u obesidad con DM 2.

( )

► 𝐎𝐫𝐢𝐠𝐢𝐧𝐚𝐥 𝐬𝐨𝐮𝐫𝐜𝐞: Liu Y, Chen Y, Ma J et al, Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial BMJ 2025;388: e081820
► 𝗦𝗲𝗰𝗼𝗻𝗱𝗮𝗿𝘆 𝘀𝗼𝘂𝗿𝗰𝗲: https://www.inaaqc.org/2025_asobat

12/10/2025

E-learning | 𝙄𝙉𝘼𝘼𝙌𝘾 ᴮᴼ
---------------------------------
𝙵𝙾𝚁 𝙷𝙴𝙰𝙻𝚃𝙷𝙲𝙰𝚁𝙴 𝙿𝚁𝙾𝚅𝙸𝙳𝙴𝚁𝚂 / 𝙿𝙰𝚁𝙰 𝙿𝚁𝙾𝚅𝙴𝙴𝙳𝙾𝚁𝙴𝚂 𝙳𝙴 𝚂𝙰𝙻𝚄𝙳
𝐅𝐫𝐨𝐦 𝐃𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧 𝐭𝐨 𝐃𝐞𝐜𝐢𝐬𝐢𝐨𝐧: 𝐀𝐧𝐭𝐢𝐜𝐨𝐚𝐠𝐮𝐥𝐚𝐭𝐢𝐨𝐧 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐞𝐬 𝐢𝐧 𝐒𝐮𝐛𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐀𝐭𝐫𝐢𝐚𝐥 𝐅𝐢𝐛𝐫𝐢𝐥𝐥𝐚𝐭𝐢𝐨𝐧
In this interactive SimClinic, you'll work through a simulated patient scenario inspired by real-world clinical practice and test your ability to apply the latest evidence and guideline recommendations to determine when and how to initiate anticoagulation in this emerging clinical context.

🚥 𝗦𝘁𝗮𝗿𝘁 𝗮𝗰𝘁𝗶𝘃𝗶𝘁𝘆: https://primeinc.org/online/detection-decision-anticoagulation-strategies-subclinical-atrial-fibrillation
---------------------------------
✔ 𝗘 -𝗹𝗲𝗮𝗿𝗻𝗶𝗻𝗴: https://www.inaaqc.org/e-learning

11/10/2025

𝐌𝐚𝐧𝐚𝐠𝐞𝐦𝐞𝐧𝐭 𝐨𝐟 𝐃𝐢𝐚𝐛𝐞𝐭𝐞𝐬 𝐚𝐧𝐝 𝐇𝐲𝐩𝐞𝐫𝐠𝐥𝐲𝐜𝐞𝐦𝐢𝐚 𝐢𝐧 𝐭𝐡𝐞 𝐇𝐨𝐬𝐩𝐢𝐭𝐚𝐥
In conclusion, while there is consensus on blood glucose monitoring in hospitalized patients and the use of basal-bolus insulin, there is disagreement regarding treatment goals and the use of home medications, and little guidance on how to transition treatment upon discharge.

( )

► 𝐎𝐫𝐢𝐠𝐢𝐧𝐚𝐥 𝐬𝐨𝐮𝐫𝐜𝐞: Wilson LM; Herzig SJ; Marcantonio ER; et al. Management of Diabetes and Hyperglycemia in the Hospital: A Systematic Review of Clinical
Practice Guidelines. Diabetes Care 2025;48(4):655–664
► 𝗦𝗲𝗰𝗼𝗻𝗱𝗮𝗿𝘆 𝘀𝗼𝘂𝗿𝗰𝗲: https://www.inaaqc.org/2025_asobat

11/10/2025

𝐌𝐚𝐧𝐞𝐣𝐨 𝐝𝐞 𝐥𝐚 𝐝𝐢𝐚𝐛𝐞𝐭𝐞𝐬 𝐞 𝐡𝐢𝐩𝐞𝐫𝐠𝐥𝐢𝐜𝐞𝐦𝐢𝐚 𝐞𝐧 𝐡𝐨𝐬𝐩𝐢𝐭𝐚𝐥
En conclusión, si bien existe consenso sobre el monitoreo de la glucemia en pacientes internados y el uso de insulina basal-bolo, hay desacuerdo sobre los objetivos del tratamiento y el uso de medicamentos en el hogar y poca orientación sobre cómo hacer la transición del tratamiento al momento del alta.

( )

► 𝐎𝐫𝐢𝐠𝐢𝐧𝐚𝐥 𝐬𝐨𝐮𝐫𝐜𝐞: Wilson LM; Herzig SJ; Marcantonio ER; et al. Management of Diabetes and Hyperglycemia in the Hospital: A Systematic Review of Clinical
Practice Guidelines. Diabetes Care 2025;48(4):655–664
► 𝗦𝗲𝗰𝗼𝗻𝗱𝗮𝗿𝘆 𝘀𝗼𝘂𝗿𝗰𝗲: https://www.inaaqc.org/2025_asobat

11/10/2025

E-learning | 𝙄𝙉𝘼𝘼𝙌𝘾 ᴮᴼ
---------------------------------
𝙵𝙾𝚁 𝙷𝙴𝙰𝙻𝚃𝙷𝙲𝙰𝚁𝙴 𝙿𝚁𝙾𝚅𝙸𝙳𝙴𝚁𝚂 / 𝙿𝙰𝚁𝙰 𝙿𝚁𝙾𝚅𝙴𝙴𝙳𝙾𝚁𝙴𝚂 𝙳𝙴 𝚂𝙰𝙻𝚄𝙳
𝐀𝐧𝐭𝐢𝐜𝐨𝐚𝐠𝐮𝐥𝐚𝐭𝐢𝐨𝐧 𝐢𝐧 𝐭𝐡𝐞 𝐁𝐚𝐥𝐚𝐧𝐜𝐞: 𝐍𝐚𝐯𝐢𝐠𝐚𝐭𝐢𝐧𝐠 𝐃𝐎𝐀𝐂 𝐔𝐬𝐞 𝐢𝐧 𝐍𝐕𝐀𝐅 𝐚𝐧𝐝 𝐋𝐢𝐯𝐞𝐫 𝐃𝐢𝐬𝐞𝐚𝐬𝐞
You'll receive immediate feedback on your clinical reasoning through expert-led video explanations, and upon completion, access a downloadable summary of key insights to support informed, individualized decision-making.
Don't miss this opportunity to strengthen your confidence in managing anticoagulation in patients with NVAF and comorbid liver disease.

🚥 𝗦𝘁𝗮𝗿𝘁 𝗮𝗰𝘁𝗶𝘃𝗶𝘁𝘆: https://primeinc.org/online/anticoagulation-balance-navigating-doac-nvaf-liver-disease
---------------------------------
✔ 𝗘 -𝗹𝗲𝗮𝗿𝗻𝗶𝗻𝗴: https://www.inaaqc.org/e-learning

10/10/2025

𝐆𝐮𝐢𝐝𝐞𝐥𝐢𝐧𝐞𝐬 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐨𝐟 𝐓𝐲𝐩𝐞 𝟐 𝐃𝐢𝐚𝐛𝐞𝐭𝐞𝐬 𝐌𝐞𝐥𝐥𝐢𝐭𝐮𝐬: 𝐒𝐀𝐃
In conclusion, the proposed algorithms synthesize updated recommendations and reflect advances in scientific evidence, incorporating new therapies and strategies, and guiding decision-making regarding the treatment of type 2 diabetes with a comprehensive approach.

( )

► 𝐎𝐫𝐢𝐠𝐢𝐧𝐚𝐥 𝐬𝐨𝐮𝐫𝐜𝐞: Commendatore, V., de Dios, A., Elbert, A. et al. (2025). Guía para el tratamiento de la diabetes mellitus tipo 2 en el adulto. Revista De La Sociedad Argentina De Diabetes, 59(1), 29–66. https://doi.org/10.47196/diab.v59i1.1167
► 𝗦𝗲𝗰𝗼𝗻𝗱𝗮𝗿𝘆 𝘀𝗼𝘂𝗿𝗰𝗲: https://www.inaaqc.org/2025_asobat

10/10/2025

𝐆𝐮í𝐚 𝐩𝐚𝐫𝐚 𝐞𝐥 𝐭𝐫𝐚𝐭𝐚𝐦𝐢𝐞𝐧𝐭𝐨 𝐝𝐞 𝐥𝐚 𝐝𝐢𝐚𝐛𝐞𝐭𝐞𝐬 𝐦𝐞𝐥𝐥𝐢𝐭𝐮𝐬 𝐭𝐢𝐩𝐨 𝟐: 𝐒𝐀𝐃
En conclusión, los algoritmos propuestos sintetizan las recomendaciones actualizadas, y reflejan el avance en la evidencia científica, incorporando nuevas terapias y estrategias, orientando la toma de decisiones sobre el tratamiento de la DM2 con un enfoque integral.

( )

► 𝐎𝐫𝐢𝐠𝐢𝐧𝐚𝐥 𝐬𝐨𝐮𝐫𝐜𝐞: Commendatore, V., de Dios, A., Elbert, A. et al. (2025). Guía para el tratamiento de la diabetes mellitus tipo 2 en el adulto. Revista De La Sociedad Argentina De Diabetes, 59(1), 29–66. https://doi.org/10.47196/diab.v59i1.1167
► 𝗦𝗲𝗰𝗼𝗻𝗱𝗮𝗿𝘆 𝘀𝗼𝘂𝗿𝗰𝗲: https://www.inaaqc.org/2025_asobat

10/10/2025

E-learning | 𝙄𝙉𝘼𝘼𝙌𝘾 ᴮᴼ
---------------------------------
𝙵𝙾𝚁 𝙷𝙴𝙰𝙻𝚃𝙷𝙲𝙰𝚁𝙴 𝙿𝚁𝙾𝚅𝙸𝙳𝙴𝚁𝚂 / 𝙿𝙰𝚁𝙰 𝙿𝚁𝙾𝚅𝙴𝙴𝙳𝙾𝚁𝙴𝚂 𝙳𝙴 𝚂𝙰𝙻𝚄𝙳
𝐀𝐝𝐝𝐫𝐞𝐬𝐬𝐢𝐧𝐠 𝐭𝐡𝐞 𝐑𝐢𝐬𝐤𝐬 𝐨𝐟 𝐈𝐦𝐩𝐚𝐢𝐫𝐞𝐝 𝐀𝐰𝐚𝐫𝐞𝐧𝐞𝐬𝐬 𝐨𝐟 𝐇𝐲𝐩𝐨𝐠𝐥𝐲𝐜𝐞𝐦𝐢𝐚 𝐢𝐧 𝐓𝐲𝐩𝐞 𝟏 𝐃𝐢𝐚𝐛𝐞𝐭𝐞𝐬
In this interactive Clinical Case Challenge, you'll test your ability to recognize the signs and risk factors of IAH and apply both evidence-based approaches and emerging strategies in a simulated patient scenario inspired by real-world clinical practice.

🚥 𝗦𝘁𝗮𝗿𝘁 𝗮𝗰𝘁𝗶𝘃𝗶𝘁𝘆: https://primeinc.org/online/addressing-risks-impaired-awareness-hypoglycemia-type-1-diabetes
---------------------------------
✔ 𝗘 -𝗹𝗲𝗮𝗿𝗻𝗶𝗻𝗴: https://www.inaaqc.org/e-learning

09/10/2025

𝐄𝐭𝐢𝐨𝐥𝐨𝐠𝐲 𝐨𝐟 𝐓𝐲𝐩𝐞 𝟐 𝐃𝐢𝐚𝐛𝐞𝐭𝐞𝐬
In response to the question of whether individuals have a personal fat threshold for fat tolerance, stepwise weight loss in people with type 2 diabetes and a BMI in the 21–27 kg/m2 range resulted in remission in 70% of patients, across a wide range of fat thresholds. Type 2 diabetes can be considered a condition with a homogeneous etiology in genetically heterogeneous individuals.

( )

► 𝐎𝐫𝐢𝐠𝐢𝐧𝐚𝐥 𝐬𝐨𝐮𝐫𝐜𝐞: Taylor R. Aetiology of type 2 diabetes: an experimental medicine odyssey. Diabetologia 2025
► 𝗦𝗲𝗰𝗼𝗻𝗱𝗮𝗿𝘆 𝘀𝗼𝘂𝗿𝗰𝗲: https://www.inaaqc.org/2025_asobat

09/10/2025

𝐄𝐭𝐢𝐨𝐥𝐨𝐠í𝐚 𝐝𝐞 𝐥𝐚 𝐝𝐢𝐚𝐛𝐞𝐭𝐞𝐬 𝐭𝐢𝐩𝐨 𝟐
En respuesta a la pregunta de si los individuos de tienen un umbral de grasa personal para la tolerancia a la grasa, la pérdida de peso escalonada en personas con DM 2 e IMC en el rango 21-27 kg/m2 dio lugar a la remisión en el 70%, con una amplia gama de umbrales de grasa. La DM 2 puede considerarse como una afección de etiología homogénea en individuos genéticamente heterogéneos.

( )

► 𝐎𝐫𝐢𝐠𝐢𝐧𝐚𝐥 𝐬𝐨𝐮𝐫𝐜𝐞: Taylor R. Aetiology of type 2 diabetes: an experimental medicine odyssey. Diabetologia 2025
► 𝗦𝗲𝗰𝗼𝗻𝗱𝗮𝗿𝘆 𝘀𝗼𝘂𝗿𝗰𝗲: https://www.inaaqc.org/2025_asobat

09/10/2025

E-learning | 𝙄𝙉𝘼𝘼𝙌𝘾 ᴮᴼ
---------------------------------
𝙵𝙾𝚁 𝙷𝙴𝙰𝙻𝚃𝙷𝙲𝙰𝚁𝙴 𝙿𝚁𝙾𝚅𝙸𝙳𝙴𝚁𝚂 / 𝙿𝙰𝚁𝙰 𝙿𝚁𝙾𝚅𝙴𝙴𝙳𝙾𝚁𝙴𝚂 𝙳𝙴 𝚂𝙰𝙻𝚄𝙳
𝐁𝐫𝐞𝐚𝐤𝐢𝐧𝐠 𝐆𝐫𝐨𝐮𝐧𝐝 𝐢𝐧 𝐓𝐲𝐩𝐞 𝟏 𝐃𝐢𝐚𝐛𝐞𝐭𝐞𝐬: 𝐍𝐞𝐰 𝐚𝐧𝐝 𝐄𝐦𝐞𝐫𝐠𝐢𝐧𝐠 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐞𝐬 𝐭𝐨 𝐑𝐞𝐬𝐭𝐨𝐫𝐞 𝐇𝐲𝐩𝐨𝐠𝐥𝐲𝐜𝐞𝐦𝐢𝐚 𝐀𝐰𝐚𝐫𝐞𝐧𝐞𝐬𝐬
Impaired awareness of hypoglycemia (IAH) is a serious and potentially life-threatening complication of type 1 diabetes (T1D). Improving patient outcomes and quality of life hinges on timely recognition and effective intervention-ranging from practical approaches, such as structured education and diabetes technology, to emerging cell-based therapies aimed at restoring endogenous insulin production.

🚥 𝗦𝘁𝗮𝗿𝘁 𝗮𝗰𝘁𝗶𝘃𝗶𝘁𝘆: https://primeinc.org/podcast/breaking-ground-type-1-diabetes-new-emerging-strategies-restore-hypoglycemia
---------------------------------
✔ 𝗘 -𝗹𝗲𝗮𝗿𝗻𝗶𝗻𝗴: https://www.inaaqc.org/e-learning

Adres

Route De Lennik 804
Brussels

Website

https://www.inaaqc.org/

Meldingen

Wees de eerste die het weet en laat ons u een e-mail sturen wanneer 𝙄𝙉𝘼𝘼𝙌𝘾 ᴮᴼ nieuws en promoties plaatst. Uw e-mailadres wordt niet voor andere doeleinden gebruikt en u kunt zich op elk gewenst moment afmelden.